Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Titel:
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Auteur:
Tabernero, Josep Yoshino, Takayuki Cohn, Allen Lee Obermannova, Radka Bodoky, Gyorgy Garcia-Carbonero, Rocio Ciuleanu, Tudor-Eliade Portnoy, David C Van Cutsem, Eric Grothey, Axel Prausová, Jana Garcia-Alfonso, Pilar Yamazaki, Kentaro Clingan, Philip R Lonardi, Sara Kim, Tae Won Simms, Lorinda Chang, Shao-Chun Nasroulah, Federico